Literature DB >> 15024544

Assessment of total effective xenoestrogen burden in adipose tissue and identification of chemicals responsible for the combined estrogenic effect.

Mariana F Fernández1, Ana Rivas, Fátima Olea-Serrano, Isabel Cerrillo, José M Molina-Molina, Patricia Araque, José L Martínez-Vidal, Nicolas Olea.   

Abstract

Test systems to screen for estrogenicity and appropriate biomarkers of human exposure are required for epidemiological studies of endocrine disruption. We addressed these issues by developing and standardising a method to assess the total estrogenic xenobiotic burden in human adipose tissue. In this study, which is the continuation of a previous work, we have improved the protocol for extensive fractionation of a higher number of tissue samples in order to investigate bioaccumulated xenoestrogens that are candidates for estrogenicity and to assess their combined estrogenic effect. This was achieved by extensive HPLC separation of xenoestrogens from endogenous hormones followed by testing of individual fractions in the E-Screen test for estrogenicity. Organochlorine pesticides, PCBs and halogenated bisphenols and alkylphenols were collected in the most lipophilic fractions, followed by progestins, androgens and estradiol esters, and then by steroidal estrogens; phyto- and myco-estrogens were collected around the end of the run. These results were confirmed by exhaustive chemical analysis. In 458 human adipose tissue samples, the total effective xenoestrogen burden was positive in 75% of samples in the pooled fraction that contained organohalogenated xenoestrogens (mean 515.3 pM Eeq/g lipid; range 0-14.5 nM) and in 82% of samples in the pooled fraction where natural estrogens eluted (mean 696.6 pM Eeq/g lipid; range 0-12.9 nM). Organochlorine pesticides emerged as candidate chemicals for the estrogenicity of the first pooled fraction, because DDT and derivatives were present in 98.3% of the samples. However, no correlation was found between the concentration of any single chemical and the estrogenicity determined in the bioassay. There may be several reasons for this lack of concordance: (i) the estrogenic effects depicted in the E-Screen bioassay are a consequence of the combined effect of several organohalogens or (ii) the proliferative effect is due to other chemicals not measured. Because additive, synergistic or antagonistic mechanisms may account for the final effect observed in the pooled fractions, the approach proposed in this work is more appropriate for exposure assessment in epidemiological studies than the determination of individual chemicals in human samples.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15024544     DOI: 10.1007/s00216-004-2558-5

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  17 in total

Review 1.  Endocrine-disrupting chemicals: Effects on neuroendocrine systems and the neurobiology of social behavior.

Authors:  Andrea C Gore; Krittika Krishnan; Michael P Reilly
Journal:  Horm Behav       Date:  2018-12-04       Impact factor: 3.587

2.  Xeno-oestrogenic activity in serum as marker of occupational pesticide exposure.

Authors:  Helle Raun Andersen; Flemming Nielsen; Jesper Bo Nielsen; Mia Birkhoej Kjaerstad; Jesper Baelum; Philippe Grandjean
Journal:  Occup Environ Med       Date:  2007-05-03       Impact factor: 4.402

3.  Serum factors and clinical characteristics associated with serum E-screen activity.

Authors:  Jue Wang; Amy Trentham-Dietz; Jocelyn D C Hemming; Curtis J Hedman; Brian L Sprague
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04-15       Impact factor: 4.254

4.  Perinatal exposure to the xenoestrogen bisphenol-A induces mammary intraductal hyperplasias in adult CD-1 mice.

Authors:  Laura N Vandenberg; Maricel V Maffini; Cheryl M Schaeberle; Angelo A Ucci; Carlos Sonnenschein; Beverly S Rubin; Ana M Soto
Journal:  Reprod Toxicol       Date:  2008-10-15       Impact factor: 3.143

5.  Widely used pesticides with previously unknown endocrine activity revealed as in vitro antiandrogens.

Authors:  Frances Orton; Erika Rosivatz; Martin Scholze; Andreas Kortenkamp
Journal:  Environ Health Perspect       Date:  2011-02-10       Impact factor: 9.031

6.  Perfluorinated compounds are related to breast cancer risk in Greenlandic Inuit: a case control study.

Authors:  Eva C Bonefeld-Jorgensen; Manhai Long; Rossana Bossi; Pierre Ayotte; Gert Asmund; Tanja Krüger; Mandana Ghisari; Gert Mulvad; Peder Kern; Peter Nzulumiki; Eric Dewailly
Journal:  Environ Health       Date:  2011-10-06       Impact factor: 5.984

7.  Impact of polychlorinated biphenyls contamination on estrogenic activity in human male serum.

Authors:  Martina Plísková; Jan Vondrácek; Rocio Fernandez Canton; Jirí Nera; Anton Kocan; Ján Petrík; Tomás Trnovec; Thomas Sanderson; Martin van den Berg; Miroslav Machala
Journal:  Environ Health Perspect       Date:  2005-10       Impact factor: 9.031

8.  Xenoestrogenic activity in blood of European and Inuit populations.

Authors:  Eva C Bonefeld-Jorgensen; Philip S Hjelmborg; Thayaline S Reinert; Birgitte S Andersen; Vladimir Lesovoy; Christian H Lindh; Lars Hagmar; Aleksander Giwercman; Mogens Erlandsen; Gian-Carlo Manicardi; Marcello Spanò; Gunnar Toft; Jens Peter Bonde
Journal:  Environ Health       Date:  2006-05-05       Impact factor: 5.984

9.  Semen quality in relation to xenohormone and dioxin-like serum activity among Inuits and three European populations.

Authors:  Gunnar Toft; Manhai Long; Tanja Krüger; Philip S Hjelmborg; Jens Peter Bonde; Anna Rignell-Hydbom; Ewa Tyrkiel; Lars Hagmar; Aleksander Giwercman; Marcello Spanó; Davide Bizzaro; Henning S Pedersen; Vladymir Lesovoy; Jan K Ludwicki; Eva C Bonefeld-Jørgensen
Journal:  Environ Health Perspect       Date:  2007-12       Impact factor: 9.031

10.  Xenohormone transactivities are inversely associated to serum POPs in Inuit.

Authors:  Tanja Krüger; Mandana Ghisari; Philip S Hjelmborg; Bente Deutch; Eva C Bonefeld-Jorgensen
Journal:  Environ Health       Date:  2008-07-15       Impact factor: 5.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.